Icon (NASDAQ:ICLR) Director Sells 841 Shares

Icon Plc (NASDAQ:ICLR) Director Eugene Pacelli Mccague sold 841 shares of the business’s stock in a transaction on Tuesday, August 11th. The shares were sold at an average price of $164.29, for a total transaction of $138,167.89. Following the completion of the transaction, the director owned 3,811 shares in the company, valued at approximately $626,109.19. The trade was a 18.08% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

Icon Trading Up 1.0%

Icon stock traded up $1.59 during trading hours on Wednesday, reaching $167.17. 804,300 shares of the company’s stock were exchanged, compared to its average volume of 1,385,101. The company has a quick ratio of 0.95, a current ratio of 0.95 and a debt-to-equity ratio of 0.23. The firm’s 50 day simple moving average is $161.47 and its 200 day simple moving average is $134.31. Icon Plc has a twelve month low of $66.57 and a twelve month high of $203.91. The firm has a market capitalization of $12.80 billion, a PE ratio of 39.24, a PEG ratio of 6.88 and a beta of 1.21.

Icon (NASDAQ:ICLR) last announced its quarterly earnings data on Thursday, July 30th. The medical research company reported $2.56 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $2.55 by $0.01. Icon had a return on equity of 8.02% and a net margin of 3.99%.The company had revenue of $2.06 billion for the quarter, compared to the consensus estimate of $2 billion. During the same period in the previous year, the business earned $3.26 EPS. The firm’s revenue was up 2.3% compared to the same quarter last year. Research analysts predict that Icon Plc will post 9.57 earnings per share for the current year.

Icon News Roundup

Here are the key news stories impacting Icon this week:

• Positive Sentiment: Icon’s latest quarterly results modestly exceeded expectations: adjusted EPS was $2.56 versus the $2.55 consensus, while revenue reached $2.06 billion, above the $2.00 billion estimate and up 2.3% year over year. Analysts expect approximately $9.57 in full-year EPS, providing a fundamental support for the stock.
• Positive Sentiment: Recent analyst actions have generally been constructive. BMO Capital Markets raised its price target to $187 and Mizuho increased its target to $190, both maintaining outperform ratings. The consensus target is $170.40, modestly above the latest trading level, although the overall consensus rating remains “Hold.”
• Positive Sentiment: Short interest is reported at zero shares, indicating no measurable bearish short-selling pressure or potential forced-selling overhang.
• Neutral Sentiment: CEO Barry Balfe sold 382 shares worth about $62,675, while CFO Nigel Clerkin sold 2,267 shares worth approximately $372,445. Directors John Climax and Linda Grais each sold 841 shares at about $164.29. The filings state that all transactions were made to cover tax-withholding obligations tied to vested equity awards, reducing their usefulness as a signal of declining confidence. SEC insider transaction filing
• Negative Sentiment: Despite the revenue beat, quarterly EPS fell from $3.26 a year earlier, and Icon’s reported net margin was only 3.99%. The stock also carries a high valuation, with a price-to-earnings ratio near 39 and a PEG ratio of 6.88, leaving it sensitive to any slowdown in clinical-research demand or earnings growth.

Institutional Investors Weigh In On Icon

A number of hedge funds have recently added to or reduced their stakes in ICLR. EFG International AG acquired a new position in shares of Icon during the fourth quarter worth approximately $27,000. Abound Financial LLC bought a new position in shares of Icon in the 4th quarter worth $54,000. GAMMA Investing LLC grew its position in Icon by 21.4% in the 2nd quarter. GAMMA Investing LLC now owns 391 shares of the medical research company’s stock valued at $68,000 after purchasing an additional 69 shares during the period. Johnson Financial Group Inc. bought a new stake in Icon during the 3rd quarter valued at $71,000. Finally, Quadrant Capital Group LLC bought a new stake in Icon during the 3rd quarter valued at $78,000. Institutional investors and hedge funds own 95.61% of the company’s stock.

Analyst Ratings Changes

Several brokerages have recently commented on ICLR. Barclays lifted their price objective on shares of Icon from $160.00 to $175.00 and gave the company an “equal weight” rating in a research note on Thursday, June 25th. Royal Bank Of Canada raised shares of Icon from a “sector perform” rating to an “outperform” rating and increased their target price for the stock from $126.00 to $185.00 in a research note on Thursday, June 25th. Leerink Partners set a $145.00 target price on shares of Icon in a research note on Thursday, May 28th. Truist Financial restated a “buy” rating and issued a $209.00 price target (up from $207.00) on shares of Icon in a report on Friday, July 31st. Finally, Robert W. Baird set a $194.00 price objective on shares of Icon in a report on Friday, July 31st. One analyst has rated the stock with a Strong Buy rating, seven have issued a Buy rating, seven have given a Hold rating and two have assigned a Sell rating to the company’s stock. Based on data from MarketBeat, the company presently has an average rating of “Hold” and an average target price of $170.40.

Icon Company Profile

Icon plc (NASDAQ: ICLR) is a global provider of outsourced drug development and clinical research services to the pharmaceutical, biotechnology and medical device industries. The company partners with clients at all stages of the product life cycle, offering expertise in protocol design, trial execution and regulatory compliance across a broad range of therapeutic areas.

Icon’s service portfolio encompasses clinical trial management, data management and biostatistics, medical imaging, pharmacovigilance and safety monitoring, laboratory sciences and specialized analytical solutions.